|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:semaglutide
|
|
gptkbp:approvalYear
|
2017
|
|
gptkbp:approvedBy
|
gptkb:type_2_diabetes
|
|
gptkbp:associatedWith
|
gptkb:Rybelsus
gptkb:Wegovy
|
|
gptkbp:ATCCode
|
gptkb:A10BJ06
|
|
gptkbp:brand
|
gptkb:semaglutide
|
|
gptkbp:CASNumber
|
gptkb:910463-68-2
|
|
gptkbp:chemicalFormula
|
C187H291N45O59
|
|
gptkbp:contraindication
|
gptkb:multiple_endocrine_neoplasia_syndrome_type_2
personal or family history of medullary thyroid carcinoma
|
|
gptkbp:duration
|
long-acting
|
|
gptkbp:form
|
solution for injection
|
|
gptkbp:frequency
|
once weekly
|
|
gptkbp:halfLife
|
about 1 week
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ozempic
|
|
gptkbp:indication
|
glycemic control
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Novo_Nordisk
|
|
gptkbp:marketedIn
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
GLP-1 receptor agonist
|
|
gptkbp:notRecommendedFor
|
type 1 diabetes
pediatric patients
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribes
|
endocrinologist
primary care physician
|
|
gptkbp:prescriptionForm
|
pre-filled pen
|
|
gptkbp:riskFactor
|
pancreatitis
hypoglycemia (when used with insulin or sulfonylureas)
acute kidney injury
gallbladder disease
retinopathy complications
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
abdominal pain
constipation
weight loss
|
|
gptkbp:storage
|
2°C to 8°C
|
|
gptkbp:usedFor
|
cardiovascular risk reduction
weight management (off-label)
|
|
gptkbp:website
|
https://www.ozempic.com/
|
|
gptkbp:bfsParent
|
gptkb:Novo_Nordisk
gptkb:Mounjaro
gptkb:司美格鲁肽
|
|
gptkbp:bfsLayer
|
6
|